Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Import safety strategy paramount for CDRH in '09

This article was originally published in The Silver Sheet

Executive Summary

Creating and implementing an import safety strategy for medical devices tops CDRH's list of priorities for the current 2009 fiscal year, center director Dan Schultz says. Last November, the Bush administration unveiled a national import safety action plan with broad recommendations, along with some short- and long-term steps to address mounting concerns about the safety of food and medical and consumer products coming from overseas, particularly China. So far, the Department of Health and Human Services has signed two memoranda of agreement with China to enhance the safety of a wide variety of medical devices, drugs, food and feed traded between the two nations, while Congress attempts to tackle import safety through legislation. "I think it's relatively obvious why that has to be done, and obviously it's something that we're doing in conjunction with the rest of the agency," Schultz said Sept. 15 at the Regulatory Affairs Professionals Society (RAPS) annual meeting in Boston

You may also be interested in...



Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel